Exhibit 4.6


 





THIS WARRANT, AND THE SECURITIES ISSUABLE UPON THE EXERCISE
OF THIS WARRANT, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES
LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED
THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS
NOT REQUIRED UNDER THE ACT, OR ANY APPLICABLE STATE SECURITIES LAWS.


 


WARRANT AGREEMENT


 


To Purchase Shares of Preferred Stock of


 


EDGE THERAPEUTICS, INC.


 


Dated as of August
28, 2014 (the “Effective Date”)


 


WHEREAS, Edge Therapeutics, Inc., a Delaware corporation, has
entered into a Loan and Security Agreement of even date herewith (the “Loan Agreement”) with Hercules Technology
Growth Capital, Inc., a Maryland corporation, in its capacity as administrative agent (the “Warrantholder”)
and the other lender parties thereto;


 


WHEREAS, the Company (as defined below) desires to grant to
Warrantholder, in consideration for, among other things, the financial accommodations provided for in the Loan Agreement, the right
to purchase shares of Preferred Stock (as defined below) pursuant to this Warrant Agreement (the “Agreement”);


 


NOW, THEREFORE, in consideration of the Warrantholder executing
and delivering the Loan Agreement and providing the financial accommodations contemplated therein, and in consideration of the
mutual covenants and agreements contained herein, the Company and Warrantholder agree as follows:


 


SECTION 1.            
GRANT OF THE RIGHT TO PURCHASE PREFERRED STOCK.


 


For value received, the Company hereby grants to the Warrantholder,
and the Warrantholder is entitled, upon the terms and subject to the conditions hereinafter set forth, to subscribe for and purchase,
from the Company, an aggregate number of fully paid and non-assessable shares of the Preferred Stock equal to the quotient derived
by dividing (a) the Warrant Coverage (as defined below) by (b) the Exercise Price (defined below). The Exercise Price of such shares
is subject to adjustment as provided in Section 8.


 


The Company represents and warrants to the Warrantholder that
the Company is contemplating the authorization and issuance of a new round of its preferred stock which shall be for Series C-1
Preferred Stock of the Company.  In the event on or after the Effective Date but on or before December 31, 2014 the Company
authorizes and issues shares of the Company’s Series C-1 Preferred Stock and the aggregate net sales proceeds from such issuance
are at least $2,000,000, then this Warrant shall automatically be deemed to be initially exercisable for the Company’s Series
C-1 Preferred Stock at the Series C-1 Price (as defined below) instead of the Company’s Series C Preferred Stock.  The
Company shall provide the Warrantholder with appropriate evidence and documentation of such Series C-1 Preferred Stock issuance. 
Upon the request of the Warrantholder, within thirty (30) days of the Company’s initial issuance of its Series C-1 Preferred
Stock the Company shall execute and delivery to the Warrantholder an amendment to this Warrant or an amended and restated Warrant
reflecting such changes along with conforming changes to the Warrant to reflect the change from Series C Preferred Stock to Series
C-1 Preferred Stock and to change to the Exercise Price accordingly.  “Series C-1 Price” means the lowest
price per share for which the Company’s Series C-1 Preferred are sold or issued by the Company.  In the event that the
Company does not on or before December 31, 2014 authorize and issue shares of the Company’s Series C-1 Preferred Stock and
receive aggregate net sales proceeds from such issuance of at least $2,000,000, then this Warrant shall remain initially exercisable
for the Company’s Series C Preferred Stock at the Series C Price.


 


As used herein, the following terms shall
have the following meanings:


 


“Act” means the Securities Act
of 1933, as amended.


 


“Company” means Edge Therapeutics,
Inc., a Delaware corporation, and any successor or surviving entity that assumes the obligations of the Company under this Agreement
pursuant to Section 8(a).


 


“Charter” means the Company’s
Articles of Incorporation, Certificate of Incorporation or other constitutional document, as may be amended from time to time.


 


“Common Stock” means the Company’s
common stock, $0.00033 par value per share.



    	1



    	 



    




 


“Exercise Price”
means the Series C Price, subject to adjustment from time to time in accordance with the provisions of this Warrant; provided,
that if the Next Preferred Round Price shall be lower than the then-effective Exercise Price, then “Exercise Price”
shall mean the Next Preferred Round Price from and after the closing of the Next Preferred Round, subject to adjustment thereafter
from time to time in accordance with the provisions of this Warrant.


 


“Initial Public Offering” means
the initial underwritten public offering of the Company’s Common Stock pursuant to a registration statement under the Act,
which public offering has been declared effective by the Securities and Exchange Commission (“SEC”).


 


“Merger Event” means any reorganization,
recapitalization, consolidation or merger (or similar transaction or series of related transactions) of the Company or any Subsidiary,
sale or exchange of outstanding shares (or similar transaction or series of related transactions) of the Company or any Subsidiary
in which the holders of the Company or Subsidiary’s outstanding shares immediately before consummation of such transaction
or series of related transactions do not, immediately after consummation of such transaction or series of related transactions,
retain shares representing more than fifty percent (50%) of the voting power of the surviving entity of such transaction or series
of related transactions (or the parent of such surviving entity if such surviving entity is wholly owned by such parent), in each
case without regard to whether the Company or Subsidiary is the surviving entity, provided that none of the following shall constitute
a Merger Event: (i) any consolidation or merger effected exclusively to change the domicile of the Company, or (ii) the sale and
issuance by the Company of its equity securities to investors in a bona fide equity financing or (iii) an Initial Public Offering.


 


“Next Preferred Round” means the
first offering and sale by the Company, on or after the Effective Date, of shares of its convertible preferred stock or other senior
equity securities to one or more investors for cash for financing purposes, in a single transaction or series of related transactions
not registered under the Act, resulting in aggregate gross cash proceeds received by the Company of at least $1,000,000; provided,
that Next Preferred Round shall not include (i) any additional sales of Series C Stock by the Company, or (ii) the Company’s
Series C-1 Preferred Stock sold during the period from the Effective Date until December 31, 2014.


 


“Next Preferred Round Price” means
the lowest effective price per share for which shares of the Next Round Preferred Series are sold and issued in the Next Preferred
Round.


 


“Next Preferred Round Series” means
the series or other designation of the shares of convertible preferred stock or other senior equity security sold and issued by
the Company in the Next Preferred Round, and any other class, series or other designation of security into or for which such Next
Preferred Round Series is converted, substituted or exchanged pursuant to a reorganization, reclassification, recapitalization
or similar transaction.


 


“Preferred Stock” means Series
C Stock; provided, that if the Next Preferred Round Price shall be lower than the then-effective Exercise Price, then “Preferred
Stock” shall mean the Next Preferred Round Series from and after the closing of the Next Preferred Round; provided,
further, that, subject to provisions of Section 8(f) below, upon and after the occurrence of an event which results in the
automatic or voluntary conversion, redemption or retirement of all (but not less than all) of the outstanding shares of such Preferred
Stock pursuant to the consummation of an Initial Public Offering, then from and after the date upon which such outstanding shares
are so converted, redeemed or retired, “Preferred Stock” shall mean the Common Stock.


 


“Purchase Price” means, with respect
to any exercise of this Agreement, an amount equal to the Exercise Price as of the relevant time multiplied by the number of shares
of Preferred Stock requested to be exercised under this Agreement pursuant to such exercise.


 


“Series C Stock” means the Company’s
Series C Preferred Stock, $0.00033 par value per share, as presently constituted under the Charter, and any other class, series
or other designation of security into or for which such Series C Preferred Stock is converted, substituted or exchanged pursuant
to a reorganization, reclassification, recapitalization or similar transaction.


 


“Series C Price” means $3.85 per
share, as may be adjusted from time to time in accordance with the provisions of this Warrant.


 


“Warrant Coverage” means $500,000.00.



    	2



    	 



    




 


SECTION 2.            
TERM OF THE AGREEMENT.


 


Except as otherwise provided for herein, the term of this Agreement
and the right to purchase Preferred Stock as granted herein (the “Warrant”) shall commence on the Effective
Date and shall be exercisable for a period ending upon the later to occur of (i) ten (10) years from the Effective Date; or (ii)
if the Initial Public Offering shall be consummated on or before the tenth (10th) anniversary of the Effective Date,
five (5) years after the Initial Public Offering.


 


SECTION 3.            
EXERCISE OF THE PURCHASE RIGHTS.


 


(a)                
Exercise. The purchase rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part,
at any time, or from time to time, prior to the expiration of the term set forth in Section 2, by tendering to the Company at its
principal office a notice of exercise in the form attached hereto as Exhibit I (the “Notice of Exercise”),
duly completed and executed. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance
with the terms set forth below, and in no event later than three (3) days thereafter, the Company shall issue to the Warrantholder
a certificate for the number of shares of Preferred Stock purchased and shall execute the acknowledgment of exercise in the form
attached hereto as Exhibit II (the “Acknowledgment of Exercise”) indicating the number of shares which
remain subject to future purchases, if any.


 


The Purchase Price may be paid at the Warrantholder’s
election either (i) by cash or check, or (ii) by surrender of all or a portion of the Warrant for shares of Preferred Stock to
be exercised under this Agreement and, if applicable, an amended Agreement representing the remaining number of shares purchasable
hereunder, as determined below (“Net Issuance”). If the Warrantholder elects the Net Issuance method, the Company
will issue Preferred Stock in accordance with the following formula:


 


X  =  Y(A-B)



A


 


	Where:	X = the number
of shares of Preferred Stock to be issued to the Warrantholder.
	 	 
	 	Y = the number of shares
of Preferred Stock requested to be exercised under this Agreement.
	 	 
	 	A = the fair market value
of one (1) share of Preferred Stock at the time of issuance of such shares of Preferred Stock.
	 	 
	 	B = the Exercise Price.








 


For purposes of the above calculation, current fair market value
of Preferred Stock shall mean with respect to each share of Preferred Stock:


 


(i)                  
if the exercise is in connection with an Initial Public Offering, and if the Company’s Registration Statement relating
to such Initial Public Offering has been declared effective by the SEC, then the fair market value per share shall be the product
of (x) the initial “Price to Public” of the Common Stock specified in the final prospectus with respect to the offering
and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise;


 


(ii)                
if the exercise is after, and not in connection with an Initial Public Offering, and:


 


(A)               
if the Common Stock is traded on a securities exchange, the fair market value shall be deemed to be the product of (x) the
prior day closing price before the day the current fair market value of the securities is being determined and (y) the number of
shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise; or


 


(B)               
if the Common Stock is traded over-the-counter, the fair market value shall be deemed to be the product of (x) the prior
day closing bid and asked price quoted on the NASDAQ system (or similar system) before the day the current fair market value of
the securities is being determined and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible
at the time of such exercise;


 


(iii)               
if at any time the Common Stock is not listed on any securities exchange or quoted in the NASDAQ National Market or the
over-the-counter market, the current fair market value of Preferred Stock shall be determined in good faith by its Board of Directors,
unless the Company shall become subject to a Merger Event, in which case the fair market value of Preferred Stock shall be deemed
to be the per share value received by the holders of the Company’s Preferred Stock on a common equivalent basis pursuant
to such Merger Event.


 


Upon partial exercise by either cash or Net Issuance, the Company
shall promptly issue an amended Agreement representing the remaining number of shares purchasable hereunder. All other terms and
conditions of such amended Agreement shall be identical to those contained herein, including, but not limited to the Effective
Date hereof.



    	3



    	 



    




 


(b)                
Exercise Prior to Expiration. To the extent this Agreement is not previously exercised as to all Preferred Stock
subject hereto, and if the fair market value of one share of the Preferred Stock is greater than the Exercise Price then in effect,
this Agreement shall be deemed automatically exercised pursuant to Section 3(a) (even if not surrendered) immediately before its
expiration. For purposes of such automatic exercise, the fair market value of one share of the Preferred Stock upon such expiration
shall be determined pursuant to Section 3(a). To the extent this Agreement or any portion thereof is deemed automatically exercised
pursuant to this Section 3(b), the Company agrees to promptly notify the Warrantholder of the number of shares of Preferred Stock,
if any, the Warrantholder is to receive by reason of such automatic exercise.


 


SECTION 4.            
RESERVATION OF SHARES.


 


During the term of this Agreement, the Company will at all times
have authorized and reserved a sufficient number of shares of its Preferred Stock to provide for the exercise of the rights to
purchase Preferred Stock as provided for herein, and shall have authorized and reserved a sufficient number of shares of its Common
Stock to provide for the conversion of the shares of Preferred Stock issuable hereunder.


 


SECTION 5.            
NO FRACTIONAL SHARES OR SCRIP.


 


No fractional shares or scrip representing fractional shares
shall be issued upon the exercise of this Agreement, but in lieu of such fractional shares the Company shall make a cash payment
therefor upon the basis of the then fair market value of one share of Preferred Stock.


 


SECTION 6.            
NO RIGHTS AS SHAREHOLDER/STOCKHOLDER.


 


This Agreement does not entitle the Warrantholder to any voting
rights or other rights as a shareholder/stockholder of the Company prior to the exercise of this Agreement.


 


SECTION 7.            
WARRANTHOLDER REGISTRY.


 


The Company shall maintain a registry showing the name and address
of the registered holder of this Agreement. Warrantholder’s initial address, for purposes of such registry, is set forth
below Warrantholder’s signature on this Agreement. Warrantholder may change such address by giving written notice of such
changed address to the Company.


 


SECTION 8.            
ADJUSTMENT RIGHTS.


 


The Exercise Price and the number of shares of Preferred Stock
purchasable hereunder are subject to adjustment, as follows:


 


(a)                
Merger Event. If at any time there shall be Merger Event, then, as a part of such Merger Event, lawful provision
shall be made so that the Warrantholder shall thereafter be entitled to receive, upon exercise of this Agreement, the number of
shares of preferred stock or other securities or property (collectively, “Reference Property”) that the Warrantholder
would have received in connection with such Merger Event if Warrantholder had exercised this Agreement immediately prior to the
Merger Event. In any such case, appropriate adjustment (as determined in good faith by the Company’s Board of Directors)
shall be made in the application of the provisions of this Agreement with respect to the rights and interests of the Warrantholder
after the Merger Event to the end that the provisions of this Agreement (including adjustments of the Exercise Price and adjustments
to ensure that the provisions of this Section 8 shall thereafter be applicable, as nearly as possible, to the purchase rights under
this Agreement in relation to any Reference Property thereafter acquirable upon exercise of such purchase rights) shall continue
to be applicable in their entirety, and to the greatest extent possible. Without limiting the foregoing, in connection with any
Merger Event, upon the closing thereof, the successor or surviving entity shall assume the obligations of this Agreement;
provided that the foregoing assumption requirement shall not apply if the consideration to be paid
for or in respect of the outstanding shares of Preferred Stock in such Merger Event consists solely of cash and/or readily marketable
securities. In connection with a Merger Event and upon Warrantholder’s written election to the Company, the Company shall
cause this Warrant Agreement to be exchanged for the consideration that Warrantholder would have received if Warrantholder had
chosen to exercise its right to have shares issued pursuant to the Net Issuance provisions of this Warrant Agreement without actually
exercising such right, acquiring such shares and exchanging such shares for such consideration. The provisions of this Section
8(a) shall similarly apply to successive Merger Events.


 


(b)                
Reclassification of Shares. Except for a Merger Event subject to Section 8(a), and subject to Section 8(f), if the
Company at any time shall, by combination, reclassification, reorganization, exchange or subdivision of securities or otherwise,
change any of the securities as to which purchase rights under this Agreement exist into the same or a different number of securities
of any other class or classes, this Agreement shall thereafter represent the right to acquire such number and kind of securities
as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights
under this Agreement immediately prior to such combination, reclassification, exchange, subdivision or other change. The provisions
of this Section 8(b) shall similarly apply to successive combination, reclassification, exchange, subdivision or other change.


 


(c)                
Subdivision or Combination of Shares. If the Company at any time shall combine or subdivide its Preferred Stock,
(i) in the case of a subdivision, the Exercise Price shall be proportionately decreased and the number of shares of Preferred Stock
issuable hereunder shall be proportionately increased, or (ii) in the case of a combination, the Exercise Price shall be proportionately
increased and the number of shares of Preferred Stock issuable hereunder shall be proportionately decreased.



    	4



    	 



    




 


(d)                
Stock Dividends. If the Company at any time while this Agreement is outstanding and unexpired shall:


 


(i)                  
pay a dividend with respect to the Preferred Stock payable in Preferred Stock, then the Exercise Price shall be adjusted,
from and after the date of determination of shareholders entitled to receive such dividend or distribution, to that price determined
by multiplying the Exercise Price in effect immediately prior to such date of determination by a fraction (A) the numerator of
which shall be the total number of shares of Preferred Stock outstanding immediately prior to such dividend or distribution, and
(B) the denominator of which shall be the total number of shares of Preferred Stock outstanding immediately after such dividend
or distribution; or


 


(ii)                
make any other distribution with respect to Preferred Stock (or stock into which the Preferred Stock is convertible), except
any distribution specifically provided for in any other clause of this Section 8, then, in each such case, provision shall
be made by the Company such that the Warrantholder shall receive upon exercise or conversion of this Warrant a proportionate share
of any such distribution as though it were the holder of the Preferred Stock (or other stock for which the Preferred Stock is convertible)
as of the record date fixed for the determination of the stockholders of the Company entitled to receive such distribution.


 


(e)                
Antidilution Rights. Additional antidilution rights applicable to the Preferred Stock purchasable hereunder are as
set forth in the Charter and shall be applicable with respect to the Preferred Stock issuable hereunder. The Company shall promptly
provide the Warrantholder with any restatement, amendment, modification or waiver of the Charter; provided, that no such
amendment, modification or waiver shall impair or reduce the antidilution rights applicable to the Preferred Stock as of the date
hereof, without the Warrantholder’s consent, unless such amendment, modification or waiver affects the rights of Warrantholder
with respect to the Preferred Stock in the same manner as it affects all other holders of Preferred Stock. The Company shall provide
Warrantholder with prior written notice of any issuance of its stock or other equity security to occur after the Effective Date
of this Agreement (other than (i) stock issued as a dividend upon the Company’s Series C Preferred Stock or Series C-1 Preferred
Stock, and (ii) stock, options and other securities issued pursuant to any incentive equity plan of the Company), which notice
shall include (a) the price at which such stock or security is to be sold, (b) the number of shares to be issued, and (c)
such other information as necessary for Warrantholder to determine if a dilutive event has occurred. For the avoidance of doubt,
there shall be no duplicate anti-dilution adjustment pursuant to this subsection (e), the forgoing subsection (d) and the Charter.


 


(f)                 
Notice of Adjustments. If: (i) the Company shall declare any dividend or distribution upon its stock, whether in
stock, cash, property or other securities, other than stock dividends upon its Series C Preferred Stock or Series C-1 Preferred
Stock; (ii) there shall be any Merger Event; (iv) there shall be an Initial Public Offering; (iii) the Company shall sell, lease,
license or otherwise transfer all or substantially all of its assets; or (iv) there shall be any voluntary dissolution, liquidation
or winding up of the Company; then, in connection with each such event, the Company shall send to the Warrantholder: (A) at least
thirty (30) days’ prior written notice of the date on which the books of the Company shall close or a record shall be taken
for such dividend, distribution, subscription rights (specifying the date on which the holders of Preferred Stock shall be entitled
thereto) or for determining rights to vote in respect of such Merger Event, dissolution, liquidation or winding up; (B) in the
case of any such Merger Event, sale, lease, license or other transfer of all or substantially all assets, dissolution, liquidation
or winding up, at least thirty (30) days’ prior written notice of the date when the same shall take place (and specifying
the date on which the holders of Preferred Stock shall be entitled to exchange their Preferred Stock for securities or other property
deliverable upon such Merger Event, dissolution, liquidation or winding up); and (C) in the case of an Initial Public Offering,
the Company shall give the Warrantholder at least thirty (30) days’ written notice prior to the effective date thereof.


 


Each such written notice shall set forth, in reasonable detail,
(i) the event requiring the notice, and (ii) if any adjustment is required to be made, (A) the amount of such adjustment, (B) the
method by which such adjustment was calculated, (C) the adjusted Exercise Price (if the Exercise Price has been adjusted), and
(D) the number of shares subject to purchase hereunder after giving effect to such adjustment, and shall be given in accordance
with Section 12(g) below.


 


SECTION 9.            
REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY.


 


(a)                
Reservation of Preferred Stock. The Preferred Stock issuable upon exercise of the Warrantholder’s rights has
been or, in the case of Preferred Stock issuable in the Next Round, will be duly and validly reserved and, when issued in accordance
with the provisions of this Agreement, will be validly issued, fully paid and non-assessable, and will be free of any taxes, liens,
charges or encumbrances of any nature whatsoever; provided, that the Preferred Stock issuable pursuant to this Agreement
may be subject to restrictions on transfer under state and/or federal securities laws. The Company has made available to the Warrantholder
true, correct and complete copies of its Charter and current bylaws. The issuance of certificates for shares of Preferred Stock
upon exercise of this Agreement shall be made without charge to the Warrantholder for any issuance tax in respect thereof (other
than income taxes of the Warrantholder), or other cost incurred by the Company in connection with such exercise and the related
issuance of shares of Preferred Stock; provided, that the Company shall not be required to pay any tax which may be payable
in respect of any transfer and the issuance and delivery of any certificate in a name other than that of the Warrantholder.



    	5



    	 



    




 


(b)                
Due Authority. The execution and delivery by the Company of this Agreement and the performance of all obligations
of the Company hereunder, including the issuance to Warrantholder of the right to acquire the shares of Preferred Stock and the
Common Stock into which it may be converted, have been duly authorized by all necessary corporate action on the part of the Company.
This Agreement: (1) does not violate the Company’s Charter or current bylaws; (2) does not contravene any law or governmental
rule, regulation or order applicable to it; and (3) does not and will not contravene any provision of, or constitute a default
under, any indenture, mortgage, contract or other instrument to which it is a party or by which it is bound. This Agreement constitutes
a legal, valid and binding agreement of the Company, enforceable in accordance with its terms.


 


(c)                
Consents and Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other
action in respect of any state, federal or other governmental authority or agency is required with respect to the execution, delivery
and performance by the Company of its obligations under this Agreement, except for the filing of notices pursuant to Regulation
D under the Act and any filing required by applicable state securities law, which filings will be effective by the time required
thereby.


 


(d)                
Issued Securities. All issued and outstanding shares of Common Stock, Preferred Stock or any other securities of
the Company have been duly authorized and validly issued and are fully paid and nonassessable. All outstanding shares of Common
Stock, Preferred Stock and any other securities were issued in full compliance with all federal and state securities laws. In addition,
as of the date immediately preceding the date of this Agreement:


 


(i)                  
The authorized capital of the Company consists of (A) 17,500,000 shares of Common Stock, of which 2,310,000 shares are issued
and outstanding, and (B) 10,000,000 shares of Preferred Stock (including Series A, Series B, Series B-1 and Series C Preferred
Stock), of which 8,336,865 shares are issued and outstanding and are convertible into 8,336,865 shares of Common Stock at $1.00
to $3.85 per share, as applicable.


 


(ii)                
The Company has reserved 599,139 shares of Common Stock for issuance pursuant to the (i) Warrants issued in connection with
the issuance of convertible debt to the New Jersey Economic Development Authority, (ii) Warrants issued in connection with the
issuance of shares of Series B-1 Preferred Stock, and (iii) Warrants issued to the placement agent in connection with the issuance
of shares of Series C Preferred Stock.


 


(iii)               
The Company has reserved 3,347,500 shares of Common Stock for issuance under its Stock Option Plan(s), under which 3,345,948
options are outstanding. Except as provided herein, there are no other options, warrants, conversion privileges or other rights
presently outstanding to purchase or otherwise acquire any authorized but unissued shares of the Company’s capital stock
or other securities of the Company. The Company has no outstanding loans to any employee, officer or director of the Company.


 


(iv)              
In accordance with the Company’s Charter, no shareholder of the Company has preemptive rights to purchase new issuances
of the Company’s capital stock.


 


(e)                
Registration Rights. The Company agrees that the shares of Common Stock issued and issuable upon conversion of the
shares of Preferred Stock issued and issuable upon exercise of this Warrant, and, at all times (if any) when the Preferred Stock
shall be Common Stock, shall have the “Piggyback,” and S-3 registration rights pursuant to and as set forth in the
Company’s investor rights agreement or similar agreement (the “Investor Rights Agreement”) on a pari passu
basis with the holders of outstanding shares of Common Stock who are parties thereto.


 


(f)                 
Other Commitments to Register Securities. Except as set forth in this Agreement, the Company is not, pursuant to
the terms of any other agreement currently in existence, under any obligation to register under the Act any of its presently outstanding
securities or any of its securities which may hereafter be issued.


 


(g)                
Exempt Transaction. Subject to the accuracy of the Warrantholder’s representations in Section 10, the issuance
of the Preferred Stock upon exercise of this Agreement, and the issuance of the Common Stock upon conversion of the Preferred Stock,
will each constitute a transaction exempt from (i) the registration requirements of Section 5 of the Act, in reliance upon Section
4(2) thereof, and (ii) the qualification requirements of the applicable state securities laws.


 


(h)                
Compliance with Rule 144. If the Warrantholder proposes to sell Preferred Stock issuable upon the exercise of this
Agreement, or the Common Stock into which it is convertible, in compliance with Rule 144 promulgated by the SEC, then, upon Warrantholder’s
written request to the Company, the Company shall furnish to the Warrantholder, within ten days after receipt of such request,
a written statement confirming the Company’s compliance with the filing requirements of the SEC as set forth in such Rule,
as such Rule may be amended from time to time.


 


(i)                  
Information Rights. During the term of this Warrant, Warrantholder shall be entitled to the information rights contained
in Section 7.1 of the Loan Agreement, and Section 7.1 of the Loan Agreement is hereby incorporated into this Agreement by this
reference as though fully set forth herein, provided, however, that the Company shall not be required to deliver a Compliance Certificate
once all Indebtedness (as defined in the Loan Agreement) owed by the Company to Warrantholder has been repaid.



    	6



    	 



    




 


SECTION 10.        
REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER.


 


This Agreement has been entered into by the Company in reliance
upon the following representations and covenants of the Warrantholder:


 


(a)                
Investment Purpose. The right to acquire Preferred Stock is being acquired for investment and not with a view to
the sale or distribution of any part thereof, and the Warrantholder has no present intention of selling or engaging in any public
distribution of such rights or the Preferred Stock except pursuant to an effective registration statement or an exemption from
the registration requirements of the Act.


 


(b)                
Private Issue. The Warrantholder understands (i) that the Preferred Stock issuable upon exercise of this Agreement
is not registered under the Act or qualified under applicable state securities laws on the ground that the issuance contemplated
by this Agreement will be exempt from the registration and qualifications requirements thereof, and (ii) that the Company’s
reliance on such exemption is predicated on the representations set forth in this Section 10.


 


(c)                
Financial Risk. The Warrantholder has such knowledge and experience in financial and business matters as to be capable
of evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment.


 


(d)                
Risk of No Registration. The Warrantholder understands that if the Company does not register with the SEC pursuant
to Section 12 of the Securities Exchange Act of 1934 (the “1934 Act”), or file reports pursuant to Section 15(d)
of the 1934 Act, or if a registration statement covering the securities under the Act is not in effect when it desires to sell
(i) the rights to purchase Preferred Stock pursuant to this Agreement or (ii) the Preferred Stock issuable upon exercise of the
right to purchase, it may be required to hold such securities for an indefinite period. The Warrantholder also understands that
any sale of (A) its rights hereunder to purchase Preferred Stock or (B) Preferred Stock issued or issuable hereunder
which might be made by it in reliance upon Rule 144 under the Act may be made only in accordance with the terms and conditions
of that Rule.


 


(e)                
Accredited Investor. Warrantholder is an “accredited investor” within the meaning of the Securities and
Exchange Rule 501 of Regulation D, as presently in effect.


 


SECTION 11.        
TRANSFERS.


 


Subject to compliance with applicable federal and state securities
laws, this Agreement and all rights hereunder are transferable, in whole or in part, without charge to the holder hereof (except
for transfer taxes) upon surrender of this Agreement properly endorsed, provided, however, that (i) any successor
transferee makes the representations and covenants set forth in Section 10 and agrees in writing to be bound by the covenants,
terms and conditions of this Warrant and (ii) the Warrantholder agrees not to transfer this Agreement and any rights hereunder
to a competitor of the Company so long as there are no Events of Default under the Loan Agreement. Each taker and holder of this
Agreement, by taking or holding the same, consents and agrees that this Agreement, when endorsed in blank, shall be deemed negotiable,
and that the holder hereof, when this Agreement shall have been so endorsed and its transfer recorded on the Company’s books,
shall be treated by the Company and all other persons dealing with this Agreement as the absolute owner hereof for any purpose
and as the person entitled to exercise the rights represented by this Agreement. The transfer of this Agreement shall be recorded
on the books of the Company upon receipt by the Company of a notice of transfer in the form attached hereto as Exhibit III (the
“Transfer Notice”), at its principal offices and the payment to the Company of all transfer taxes and other
governmental charges imposed on such transfer. Until the Company receives such Transfer Notice, the Company may treat the registered
owner hereof as the owner for all purposes.


 


SECTION 12.        
MISCELLANEOUS.


 


(a)                
Effective Date. The provisions of this Agreement shall be construed and shall be given effect in all respects as
if it had been executed and delivered by the Company on the date hereof. This Agreement shall be binding upon any successors or
assigns of the Company.


 


(b)                
Remedies. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its
rights either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any
such default, and/or an action for specific performance for any default where Warrantholder will not have an adequate remedy at
law and where damages will not be readily ascertainable. The Company expressly agrees that it shall not oppose an application by
the Warrantholder or any other person entitled to the benefit of this Agreement requiring specific performance of any or all provisions
hereof or enjoining the Company from continuing to commit any such breach of this Agreement.


 


(c)               
No Impairment of Rights. The Company will not, by amendment of its Charter or through any other means, avoid or seek
to avoid the observance or performance of any of the terms of this Agreement, but will at all times in good faith assist in the
carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate in order to protect the
rights of the Warrantholder against impairment. The foregoing notwithstanding, the Company shall
not have been deemed to have impaired the Warrantholder’s rights hereunder: (i) if it amends its Charter, or the holders
of the Company’s other series of preferred stock waive rights thereunder, in a manner that does not affect the Preferred
Stock differently from the effect that such amendments or waivers have generally on the rights, preferences, privileges or restrictions
of the other shares of the same class of stock, or (ii) if the Company, through a reorganization, transfer of assets, consolidation,
merger, dissolution, issue, or sale of securities or any other voluntary action, affects Warrantholder’s rights hereunder
in a manner that does not affect the Preferred Stock differently from the effect that such transactions have generally on the rights,
preferences, privileges or restrictions of the other shares of the same class of stock.


 


(d)                
Additional Documents. The Company, upon execution of this Agreement, shall provide the Warrantholder with certified
resolutions with respect to the representations, warranties and covenants set forth in Sections 9(a), 9(c) and 9(e). The Company
shall also supply such other documents as the Warrantholder may from time to time reasonably request.



    	7



    	 



    




 


(e)                
Attorney’s Fees. In any litigation, arbitration or court proceeding between the Company and the Warrantholder
relating hereto, the prevailing party shall be entitled to attorneys’ fees and expenses and all costs of proceedings incurred
in enforcing this Agreement. For the purposes of this Section 12(e), attorneys’ fees shall include without limitation fees
incurred in connection with the following: (i) contempt proceedings; (ii) discovery; (iii) any motion, proceeding or other activity
of any kind in connection with an insolvency proceeding; (iv) garnishment, levy, and debtor and third party examinations; and (v)
post-judgment motions and proceedings of any kind, including without limitation any activity taken to collect or enforce any judgment.


 


(f)                 
Severability. In the event any one or more of the provisions of this Agreement shall for any reason be held invalid,
illegal or unenforceable, the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or unenforceable
provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention
of the parties underlying the invalid, illegal or unenforceable provision.


 


(g)                
Notices. Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service
of process or other communication that is required, contemplated, or permitted under this Agreement or with respect to the subject
matter hereof shall be in writing, which shall include email communication, and shall be deemed to have been validly served, given,
delivered, and received upon the earlier of: (i) the day of transmission by facsimile, email communication, or hand delivery
if transmission or delivery occurs on a business day at or before 5:00 pm in the time zone of the recipient, or, if transmission
or delivery occurs on a non-business day or after such time, the first business day thereafter, or the first business day after
deposit with an overnight express service or overnight mail delivery service; or (ii) the third calendar day after deposit
in the United States mails, with proper first class postage prepaid, and shall be addressed to the party to be notified as follows:


 


If to Warrantholder:


 


HERCULES TECHNOLOGY GROWTH CAPITAL, INC.



Legal Department



Attention: Chief Legal Officer and Manuel Henriquez



400 Hamilton Avenue, Suite 310



Palo Alto, California 94301



Facsimile: 650-473-9194



Telephone: 650-289-3060

Email:


 


With a copy to:


 


RIEMER & BRAUNSTEIN LLP



Attention: Adam W. Jacobs, Esquire



Three Center Plaza



Boston, Massachusetts 02018



Facsimile: 617-692-3513



Telephone: 617-880-3513

Email: ajacobs@riemerlaw.com


 


(i)If to the Company:


 


EDGE THERAPEUTICS, INC.




Attention: Andrew Einhorn



200 Connell Drive, Suite 1600


Berkeley Heights, New Jersey 07922



Facsimile: 908-790-1212



Telephone: 800-208-3343

Email: aeinhorn@edgetherapeutics.com


 


or to such other address as each party may designate for itself
by like notice.



    	8



    	 



    




 


(h)                
Entire Agreement; Amendments. This Agreement constitutes the entire agreement and understanding of the parties hereto
in respect of the subject matter hereof, and supersedes and replaces in their entirety any prior proposals, term sheets, letters,
negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof (including Warrantholder’s
proposal letter dated July 21, 2014). None of the terms of this Agreement may be amended except by an instrument executed by each
of the parties hereto.


 


(i)                  
Headings. The various headings in this Agreement are inserted for convenience only and shall not affect the meaning
or interpretation of this Agreement or any provisions hereof.


 


(j)                 
No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement.
In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly
by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any provisions of this Agreement.


 


(k)                
No Waiver. No omission or delay by Warrantholder at any time to enforce any right or remedy reserved to it, or to
require performance of any of the terms, covenants or provisions hereof by the Company at any time designated, shall be a waiver
of any such right or remedy to which Warrantholder is entitled, nor shall it in any way affect the right of Warrantholder to enforce
such provisions thereafter.


 


(l)                  
Survival. All agreements, representations and warranties contained in this Agreement or in any document delivered
pursuant hereto shall be for the benefit of Warrantholder and shall survive the execution and delivery of this Agreement and the
expiration or other termination of this Agreement.


 


(m)              
Governing Law. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the
State of New York, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.


 


(n)                
Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Agreement may
be brought in any state or federal court of competent jurisdiction located in the State of New York. By execution and delivery
of this Agreement, each party hereto generally and unconditionally: (a) consents to personal jurisdiction in New York County, State
of New York; (b) waives any objection as to jurisdiction or venue in New York County, State of New York; (c) agrees not to assert
any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment
rendered thereby in connection with this Agreement. Service of process on any party hereto in any action arising out of or relating
to this Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 12(g), and shall
be deemed effective and received as set forth in Section 12(g). Nothing herein shall affect the right to serve process in any other
manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction.


 


(o)                
Mutual Waiver of Jury Trial. Because disputes arising in connection with complex financial transactions are most
quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to
apply (rather than arbitration rules), the parties desire that their disputes be resolved by a judge applying such applicable laws.
EACH OF THE COMPANY AND WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM,
CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY THE COMPANY AGAINST
WARRANTHOLDER OR ITS ASSIGNEE OR BY WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY. This waiver extends to all such Claims,
including Claims that involve Persons other than the Company and Warrantholder; Claims that arise out of or are in any way connected
to the relationship between the Company and Warrantholder; and any Claims for damages, breach of contract, specific performance,
or any equitable or legal relief of any kind, arising out of this Agreement.


 


(p)                
Prejudgment Relief. In the event Claims are to be resolved by arbitration, either party may seek from a court of
competent jurisdiction identified in Section 12(n), any prejudgment order, writ or other relief and have such prejudgment order,
writ or other relief enforced to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to resolution
by judicial reference.


 


(q)                
Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number
of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original,
but all of which counterparts shall constitute but one and the same instrument.


 


[Remainder of Page Intentionally Left Blank]


 



    	9



    	 



    




 


IN WITNESS WHEREOF, the parties hereto have caused this Agreement
to be executed by its officers thereunto duly authorized as of the Effective Date.


 





	COMPANY:	EDGE THERAPEUTICS, INC.
	 	 	 
	 	 	 
	 	By:	/s/ Brian A. Leuthner
	 	Name:	 Brian A. Leuthner
	 	Title:	President and Chief Executive Officer



 




 
	WARRANTHOLDER:	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
	 	 	 
	 	 	 
	 	By:	 /s/ Ben Bang
	 	Name:	Ben Bang
	 	Title:	Senior Counsel



 






    	10



    	 



    




 


EXHIBIT I


 


NOTICE OF EXERCISE


 


To:EDGE THERAPEUTICS, INC.


 


		(1)	The undersigned Warrantholder hereby elects to purchase [_______] shares of the Series [__] Preferred Stock of [_________________],
pursuant to the terms of the Agreement dated the [___] day of [______, _____] (the “Agreement”) between [_________________]
and the Warrantholder, and [CASH PAYMENT: tenders herewith payment of the Purchase Price in full, together with all applicable
transfer taxes, if any.] [NET ISSUANCE: elects pursuant to Section 3(a) of the Agreement to effect a Net Issuance.]



 


		(2)	Please issue a certificate or certificates representing said shares of Series [__] Preferred Stock in the name of the undersigned
or in such other name as is specified below.



 


The representations and warranties set forth in Section 10 of
the Agreement are true and correct in all material respects as of the date of this Notice of Exercise, with the same effect as
though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date.


 


	 	 	 
	 	 	(Name)
	 	 	 
	 	 	 
	 	 	(Address)






 

	WARRANTHOLDER:	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
	 	 	 
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 
	 	Date:	 






 



    	11



    	 



    




 


EXHIBIT II


 


ACKNOWLEDGMENT OF EXERCISE


 


The undersigned [____________________________________], hereby
acknowledge receipt of the “Notice of Exercise” from Hercules Technology Growth Capital, Inc., to purchase [____] shares
of the Series [__] Preferred Stock of [_________________], pursuant to the terms of the Agreement, and further acknowledges that
[______] shares remain subject to purchase under the terms of the Agreement.


 


 

	COMPANY:	[_________________]
	 	 	 
	 	 	 
	 	By:	 
	 	Title:	 
	 	Date:	 





 



    	12



    	 



    




 


EXHIBIT III


 


TRANSFER NOTICE


 


(To transfer or assign the foregoing Agreement execute this
form and supply required information. Do not use this form to purchase shares.)


 


FOR VALUE RECEIVED, the foregoing Agreement and all rights evidenced
thereby are hereby transferred and assigned to


 





	 	 
	(Please Print)	 
	whose address is	 
	 	 






 


 

	 	 	 
	 	Dated:	 
	 	Holder’s Signature:	 
	 	Holder’s Address:	 
	 	 	 



 






Signature Guaranteed:                                                                                                                                                                     


 


NOTE:  The signature to this Transfer Notice must
correspond with the name as it appears on the face of the Agreement, without alteration or enlargement or any change whatever.
Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority
to assign the foregoing Agreement.


 


1722332.4


 




 



    	13